A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
The main aims of this study are to learn how many people with HAE Type I or Type II are
 attack-free when treated with lanadelumab in real life. This includes the number of people
 that are attack-free when lanadelumab is given every 2 and every 4 weeks.

 This study is about collecting existing data only; participants will not receive lanadelumab
 as part of this study. No new information will be collected during this study. Only data
 already available at the participant's doctor's office will be reviewed and collected for
 this study.

 Participants do not need to visit their doctor in addition to their normal visits.
Inclusion Criteria:

 -  Participant is aged >= 12 years at the time of the last documented HAE attack in the
 eligibility period.

 -  Participant has a physician-confirmed diagnosis (or confirmation in medical records)
 of HAE type I or type II.

 -  Participant had initiated LTP with lanadelumab during the eligibility period.

 -  Participant provides informed consent or assent prior to the initiation of any study
 procedures (where required by local regulations).

 Exclusion Criteria:

 -  Participant was enrolled in a therapeutic investigational drug or device trial during
 the observation period.

 -  Participant without documented HAE attacks in the pre-index period and/or without
 available participant diary or systematic documentation of HAE attacks in the medical
 records during the post index period.